

| | | | | | |
|---|---|----|---|---|--|
| Substitute for form 1449A&B/PTO | | | | Complete if Known Application Number 10/086,294 Filing Date February 28, 2002 First Named Inventor Nielsen, Loretta Art Unit 1632 Examiner Name Joanne Hama Attorney Docket Number 016930-003712US | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | | |
| Sheet | 1 | of | 7 | | |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|-----------------|-----------------------------|---|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | AA | US-5,496,731 | 05-05-1996 | Xu et al. | |
| | AB | US-5,565,478 | Oct-1996 | Kohn et al. | |
| | AC | US-5,958,892 | Sep-1999 | Mukhopadhyay et al. | |
| | AD | US-6,316,462 B1 | 11-13-2001 | Bishop et al. | |
| | AE | US-7,157,079 B2 | 01-02-2007 | Nielsen et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|-----------------------|---------------------------|---------------------|-----------------------------------|-----------------------------|---|---|--------------------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ² |
| | | Country Code ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | AF | EP | 0685493 | A1 | 12-6-1995 | Canji Inc. | | <input type="checkbox"/> |
| | AG | EP | 0727486 | A2 | 8-21-1995 | Cancer Inst (JP); Eisai Co Ltd (JP) | | <input type="checkbox"/> |
| | AH | WO | 94/06910 | A1 | 3-31-1994 | Canji, Inc. et al. | | <input type="checkbox"/> |
| | AI | WO | 95/05738 | A1 | 3-5-1995 | Massachusetts Inst Technology | | <input type="checkbox"/> |
| | AJ | WO | 95/11984 | A3 | 5-4-1995 | Canji Inc. | | <input type="checkbox"/> |
| | AK | WO | 96/21456 | A1 | 7-18-1996 | Univ Pittsburgh | | <input type="checkbox"/> |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|--------------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | AL | ALBERTS et al., "Safety aspects of Pegylated Liposomal Doxorubicin in Patients with Cancer," Drugs 54 Suppl. 4 30-35 | <input type="checkbox"/> |
| | AM | ALLAN et al., "Cortoli Cell Death by Apoptosis in the Immature Rat Testis Following X-irradiation," Scanning Microsc. 2:503-512. | <input type="checkbox"/> |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|---|---|----|--------------------------|-------------------|--|
| Substitute for form 1449A&B/PTO | | | Complete if Known | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Application Number | 10/086,294 | |
| | | | Filing Date | February 28, 2002 | |
| | | | First Named Inventor | Nielsen, Loretta | |
| | | | Art Unit | 1632 | |
| | | | Examiner Name | Joanne Hama | |
| | | | Attorney Docket Number | 016930-003712US | |
| Sheet | 2 | of | 7 | | |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|--------------------------|---|--------------------------|--------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| | AN | ALLEN, T. M., "Liposomes," Drugs 54 Suppl. 4 8-14. | <input type="checkbox"/> | |
| | AO | ANDERSON, W.F., "Human gene therapy," Nature 392(6679 Suppl):25-30 | <input type="checkbox"/> | |
| | AP | BAXTER et al., "Cell death by apoptosis in acute leukaemia." J Pathol. 1989 June; 158(2):123-9 | <input type="checkbox"/> | |
| | AQ | BLAGOSKLONNY, Mikhail V. et al., "Raf-1/bc1-2 Phosphorylation: A step from microtubule damage to cell death," Cancer Research 57, 130-135, January 1, 1997. | <input type="checkbox"/> | |
| | AR | BLAGOSKLONNY et al., "Taxol Induction of p21WAF1 and p53 requires c-ras-1," Cancer Research 55(20): 4623-6, 1995. | <input type="checkbox"/> | |
| | AS | BULINSKI, J.J., et al., Overexpression of MAP4 inhibits organelle motility and trafficking in vivo." J Cell Sci. 1997 Dec; 110(Pt24): 3055-3064. | <input type="checkbox"/> | |
| | AT | CHEN et al., "Genetic mechanisms of tumor suppression by the human p53 gene." Science 1990 Dec 14;250(4987):1576-80. | <input type="checkbox"/> | |
| | AU | CLARKE et al., "Thymocyte apoptosis induced by P53-dependent and independent pathways." Nature 1993 April 29;362(6423):849-52. | <input type="checkbox"/> | |
| | AV | CLAYMAN et al., "Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma," Journal of Clinical Oncology 16(6):2221-2232 | <input type="checkbox"/> | |
| | AW | COLUMBANO et al., "Occurrence of cell death (apoptosis) in preneoplastic and neoplastic liver cells. A sequential study." Am J Pathol. 1984 Sep;116(3):441-6. | <input type="checkbox"/> | |
| | AX | DASS, C.R., et al., "Enhanced anticancer therapy mediated by specialized liposomes." J Pharm Pharmacol. 1997 Oct;49(10):972-975 | <input type="checkbox"/> | |
| Examiner Signature | | | | Date Considered |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | |
|---|---|----|---|--|
| Substitute for form 1449A&B/PTO | | | Complete if Known Application Number 10/086,294 Filing Date February 28, 2002 First Named Inventor Nielsen, Loretta Art Unit 1632 Examiner Name Joanne Hama Attorney Docket Number 016930-003712US | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | |
| Sheet | 3 | of | 7 | |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|---|--------------------------|--|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| | AY | DENNING, C. et al., "Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum Gene Ther. 1997 Oct; 8(15): 1825-1835. | <input type="checkbox"/> | |
| | AZ | DONEHOWER et al., "Tumor suppressor gene p53 and apoptosis," The Cancer Bulletin 46:161-166 (1994). | <input type="checkbox"/> | |
| | BA | DRAZAN et al., "In-Vivo Adenoviral-Mediated Human p53 tumor Suppressor Gene Transfer and Expression in Rat Liver After Resection," Surgery 116:197-204 (1994). | <input type="checkbox"/> | |
| | BB | FUJIWARA et al., "GeneTherapeutics and Gene Therapy for Cancer," (1994) Curr. Opin. In Oncol. 6:96-105. | <input type="checkbox"/> | |
| | BC | GOBE et al., "Cell death by apoptosis following X-irradiation of the foetal and neonatal rat kidney." Int J Radiat Biol. 1988 Oct;54(4):567-76. | <input type="checkbox"/> | |
| | BD | IJIRI et al., "Apoptosis (cell death) induced in mouse bowel by 1, 2-dimethylhydrazine, methylazoxymethanol acetate, and gamma-rays." Cancer Res. 1989 Nov 15;49(22):6342-6. | <input type="checkbox"/> | |
| | BE | IJIRI et al., "Cell death (apoptosis) in mouse intestine after continuous irradiation with gamma rays and with beta rays from tritiated water." Radiat Res. 1989 Apr;118(1):180-91. | <input type="checkbox"/> | |
| | BF | IWADATE, Y., "Mutation of the p53 gene in human astrocytic tumours correlates with increased resistance to DNA-damaging agents but not to anti-microtubule anti-cancer agents," Br. J. Cancer, 77(4):547, 1998. | <input type="checkbox"/> | |
| | BG | KIANMANESH A.R., et al., "A "distant" bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor." Hum Gene Ther. 1997 Oct 10; 8(15): 1807-1814. | <input type="checkbox"/> | |
| | BH | LANNI et al., "p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9679-83. | <input type="checkbox"/> | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|---|---|----|---|--------------------------|-------------------|
| Substitute for form 1449A&B/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Application Number | 10/086,294 |
| | | | | Filing Date | February 28, 2002 |
| | | | | First Named Inventor | Nielsen, Loretta |
| | | | | Art Unit | 1632 |
| | | | | Examiner Name | Joanne Hama |
| Sheet | 4 | of | 7 | Attorney Docket Number | 016930-003712US |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|--------------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | BI | LECHANTEUR, C. et al. "HSV-1 thymidine kinase gene therapy for colorectal adenocarcinoma-derived peritoneal carcinomatosis." <i>Gene Ther.</i> 1997 Nov; 4(11): 1189-1194. | <input type="checkbox"/> |
| | BJ | LIU et al., "Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus." <i>Cancer Res.</i> 1994 Jul 15;54(14):3662-7. | <input type="checkbox"/> |
| | BK | LOPES, N.M., et al. "Assessment of microtubule stabilizers by semiautomated in vitro microtubule protein polymerization and mitotic block assays." <i>Cancer Chemother Pharmacol.</i> 1997; 41(1): 37-47. | <input type="checkbox"/> |
| | BL | LOWE et al., "p53-dependent apoptosis modulates the cytotoxicity of anticancer agents." <i>Cell.</i> 1993 Sep 24;74(6):957-67. | <input type="checkbox"/> |
| | BM | MALLAMS, A.K., et al. "Antitumor 8-chlorobenzocycloheptapyridines: a new class of selective, nonpeptidic, nonsulphydryl inhibitors of ras farnesylation." <i>Bioorg Med Chem.</i> 1997 Jan; 5(1): 93-99. | <input type="checkbox"/> |
| | BN | MUHLRADT, P.F. et al. "Epothilone B stabilizes microtubuli of macrophages like taxol without showing taxol-like endotoxin activity." <i>Cancer Res.</i> 1997 Aug 15; 57(16): 3344-3346. | <input type="checkbox"/> |
| | BO | NIELSEN and MANEVAL, "p53 tumor suppressor gene therapy for cancer," <i>Cancer Gene Therapy</i> 5(1):52-63 (1998) | <input type="checkbox"/> |
| | BP | NIKIFOROV, M.A. et al. "Suppression of apoptosis by bcl-2 does not prevent p53-mediated control of experimental metastasis and anchorage dependence." <i>Oncogene.</i> 1997 Dec 18; 15(25): 3007-3012. | <input type="checkbox"/> |
| | BQ | NJOROGE, F.G. et al. "Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4-(8-chloro -5,6-dihydro -11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)- piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compounds." <i>J Med Chem.</i> 1997 Dec 19; 40(26): 4290-4301. | <input type="checkbox"/> |
| | BR | ONO, Y. et al. "Regression of experimental brain tumors with 6-thioxanthine and Escherichia coli gpt gene therapy" <i>Hum Gene Ther.</i> 1997 Nov 20; 8(17): 2043-2055. | <input type="checkbox"/> |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|---|---|----|--------------------------|------------------------|-----------------|
| Substitute for form 1449A&B/PTO | | | Complete if Known | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Application Number | 10/086,294 | |
| | | | Filing Date | February 28, 2002 | |
| | | | First Named Inventor | Nielsen, Loretta | |
| | | | Art Unit | 1632 | |
| | | | Examiner Name | Joanne Hama | |
| Sheet | 5 | of | 7 | Attorney Docket Number | 016930-003712US |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|--------------------------|---|--------------------------|--------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| | BS | ORKIN and MOTULSKY, "Report and recommendations of the panel to assess the NIH investment in research on gene therapy" [online], December 7, 1995 http://www.nih.gov/news/panelrep.html | <input type="checkbox"/> | |
| | BT | PANDA, D. et al., "Differential Effects of Vinblastine on polymerization and dynamics at opposite microtubule ends," J. Biol. Chem. 1996 Nov. 22; 271(47): 29807-29812. | <input type="checkbox"/> | |
| | BU | PANDA, D. et al., "Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action." Proc Natl Acad Sci U S A. 1997 Sep 30; 94(20): 10560-10564. | <input type="checkbox"/> | |
| | BV | QAZILBASH, M.H. et al. "Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53." Gene Ther. 1997 Jul; 4(7): 675-682. | <input type="checkbox"/> | |
| | BW | RABINOVITCH, A. et al. "Combination therapy with cyclosporine and interleukin-4 or interleukin-10 prolongs survival of syngeneic pancreatic islet grafts in nonobese diabetic mice." Transplantation. 1997 Dec 15; 64(11): 1525-1531. | <input type="checkbox"/> | |
| | BX | REID et al., "Intravascular adenoviral agents in cancer patients: Lessons from clinical trials," Cancer Gene Therapy 9:979-986 (2002) | <input type="checkbox"/> | |
| | BY | ROTH et al., (1996) Modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin. Hum Gene Ther. 1996 May 20;7(8):1013-30 | <input type="checkbox"/> | |
| | BZ | ROTH, Proc. Am. Ass'n Cancer Res. 35:692 (1994). | <input type="checkbox"/> | |
| | CA | SARRAF et al., "Kinetic studies on a murine sarcoma and an analysis of apoptosis." Br J Cancer. 1986 Dec;54(6):989-98. | <input type="checkbox"/> | |
| | CB | SCHULER et al., "A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer," Human Gene Therapy 9:2075-2082 (1998) | <input type="checkbox"/> | |
| | CC | SETH et al., "A recombinant adenovirus expressing wild type p53 induces apoptosis in drug-resistant human breast cancer cells: A gene therapy approach for drug-resistant cancers." Cancer Gene Ther. 1997 Nov-Dec;4(6):383-90. | <input type="checkbox"/> | |
| Examiner Signature | | | | Date Considered |

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|--|---|-------------------------------|-------------------|
| Substitute for form 1449A&B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | <i>Application Number</i> | 10/086,294 |
| | | <i>Filing Date</i> | February 28, 2002 |
| | | <i>First Named Inventor</i> | Nielsen, Loretta |
| | | <i>Art Unit</i> | 1632 |
| | | <i>Examiner Name</i> | Joanne Hama |
| <i>(Use as many sheets as necessary)</i> | | <i>Attorney Docket Number</i> | 016930-003712US |
| Sheet | 6 | of | 7 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|--------------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | CD | SHAW et al., "Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line." Proc Natl Acad Sci U S A. 1992 May 15;89(10):4495-9. | <input type="checkbox"/> |
| | CE | SU, H. et al. "Tissue-specific expression of herpes simplex virus thymidine kinase gene delivered by adeno-associated virus inhibits the growth of human hepatocellular carcinoma in athymic mice. Proc Natl Acad Sci U S A. 1997 Dec 9; 94(25): 13891-13896. | <input type="checkbox"/> |
| | CF | SUN, Jiazhi et al., "Ras CAAXPeptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras Mutation and p53 deletion," Cancer Research 55, 4243-4247, October 1, 1995. | <input type="checkbox"/> |
| | CG | VASQUEZ, R.J. et al. "Nanomolar concentrations of nocodazole alter microtubule dynamic instability in vivo and in vitro." Mol Biol Cell. 1997 Jun; 8(6): 973-985. | <input type="checkbox"/> |
| | CH | WAHL et al., "Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis," Nature Medicine 2(1):72-79 (1996) | <input type="checkbox"/> |
| | CI | WEEDON et al., "Apoptosis. Its nature and implications for dermatopathology." Am J Dermatopathol. 1979 Summer;1(2):133-44. Review. | <input type="checkbox"/> |
| | CJ | WIZNEROWICZ, M. et al. "Double-copy bicistronic retroviral vector platform for gene therapy and tissue engineering: application to melanoma vaccine development." Gene Ther. 1997 Oct; 4(10): 1061-1068. | <input type="checkbox"/> |
| | CK | YEAGER, T.R. et al. "Overcoming cellular senescence in human cancer pathogenesis." Genes Dev. 1998 Jan 15; 12(2): 163-174. | <input type="checkbox"/> |
| | CL | YONISH-ROUACH et al., "Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6." Nature. 1991 Jul 25;352(6333):345-7. | <input type="checkbox"/> |
| | CM | ZHANG, F.L. et al. "Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I." J Biol Chem. 1997 Apr 11; 272(15): 10232-10239. | <input type="checkbox"/> |
| | CN | ZWACKA Ralf M. et al., "Gene Therapy for Colon Cancer," Hematol. Oncol. Clin. North Amer., 12(3):595-615, 1998. | <input type="checkbox"/> |
| Examiner Signature | | | Date Considered |

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|---|---|----|---|--------------------------|-------------------|
| Substitute for form 1449A&B/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Application Number | 10/086,294 |
| | | | | Filing Date | February 28, 2002 |
| | | | | First Named Inventor | Nielsen, Loretta |
| | | | | Art Unit | 1632 |
| | | | | Examiner Name | Joanne Hama |
| Sheet | 7 | of | 7 | Attorney Docket Number | 016930-003712US |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|--------------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | CO | US Patent Application 11/493,429 (Atty. Docket No. 016930-003715US), Final Office Action dated 12-27-2007, 35 pages | <input type="checkbox"/> |
| | CP | US Patent Application 11/493,429 (Atty. Docket No. 016930-003715US), Office Action dated 7-06-2007, 18 pages | <input type="checkbox"/> |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.